Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 50.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,002 shares of the medical equipment provider's stock after selling 24,170 shares during the period. Ensign Peak Advisors Inc's holdings in Lantheus were worth $1,927,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares during the period. UMB Bank n.a. lifted its position in shares of Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 247 shares during the period. Fidelis Capital Partners LLC bought a new position in shares of Lantheus during the first quarter valued at approximately $34,000. Nkcfo LLC purchased a new position in Lantheus during the second quarter valued at approximately $47,000. Finally, FinTrust Capital Advisors LLC raised its stake in Lantheus by 53.6% in the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after buying an additional 232 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Leerink Partners raised their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. Finally, JMP Securities decreased their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Insider Buying and Selling

In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of Lantheus stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares in the company, valued at approximately $1,138,389.12. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the sale, the director now directly owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company's stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

Lantheus stock traded up $2.93 during mid-day trading on Friday, reaching $107.36. 673,088 shares of the company traded hands, compared to its average volume of 1,012,192. The firm's fifty day moving average is $104.45 and its two-hundred day moving average is $85.69. The company has a market capitalization of $7.44 billion, a price-to-earnings ratio of 16.39 and a beta of 0.50. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus's revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.40 earnings per share. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.